Smith & Nephew : Two new studies demonstrate INTERTAN™ Intertrochanteric Antegrade Nail improves patient outcomes and lowers healthcare costs when treating hip fractures

17 October 2018

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announced at the Orthopaedic Trauma Association Annual Meeting in Orlando, FL USA two new studies showing positive clinical results and cost savings through using its INTERTAN Intertrochanteric Antegrade Nail.

Patients recovering from a hip fracture often deal with various complications, including decline in mobility and daily living activities, and reduced ability to walk following fracture union. More than 6% will require reoperation due to complications and approximately 1 in 4 patients over the age of 65 die within 12 months of fracture.^1,2,3

In a meta-analysis published in Rheumatology and Orthopedic Medicine, the INTERTAN implant, which uses the Smith & Nephew proprietary 'Integrated Compression Screw', was compared to other intertrochanteric nails using a customary 'single screw'. The results showed that INTERTAN significantly reduced the risk of implant related failures by 81% (p<0.00001) and revision surgery by 65% (p<0.0001) when compared to single screw nails.⁴

According to a further study, published in Journal of Orthopaedic Surgery and Research, the improved clinical outcomes from the meta-analysis also led to a cost savings of $2700 USD per patient when using the INTERTAN nail compared to single screw nails.⁵

'Hip fractures and their sequelae in elderly patients can be debilitating, and potentially life threatening, and contribute a significant portion to overall health care expenditure. These new studies demonstrate that the Integrated Compression Screw used in the INTERTAN nail not only improved the clinical outcomes for these patients studied, but also reduced the cost to the overall health economic system by reducing the revision rates, compared to those that have been demonstrated in prior studies,' commented J. Tracy Watson MD, Orthopaedic Traumatologist, Phoenix, Arizona and co-author for both papers.

'Smith & Nephew is dedicated to developing products that will improve patient lives. The INTERTAN nail is a prime example of the type of game-changing technology we at Smith & Nephew strive to create. These two publications show how true innovation can both make clinical improvement and provide economic benefits,' said Andy Weymann MD, Chief Medical Officer, Smith & Nephew.

For more information on the INTERTAN nail, please visit us at the Orthopaedic Trauma Association Annual Meeting, Booth #805 or online at hipfx.com.

Enquiries

Media

Dave Snyder
[phone]
Smith & Nephew plc

Charles Reynolds
[phone]
Smith & Nephew plc

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.}

^{◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.}

References